TRIMTECH Therapeutics
Drug Discovery
- Membership category
- Corporate
Suite D, Building 960, Babraham Research Campus, Cambridge, CB22 3FH, United Kingdom
TRIMTECH Therapeutics at a glance
TRIMTECH are creating a differentiated portfolio of potent, highly specific degraders, known as TRIMTACs® and TRIMGLUEs®, that selectively target the removal of toxic proteins for the treatment of intractable CNS and inflammatory disorders.
About TRIMTECH Therapeutics
TRIMTECH has a growing pipeline of potent, CNS (central nervous system) penetrant therapeutics based on its aggregate-selective degrader molecules known as TRIMTACs and TRIMGLUEs. The pipeline is focused around the development of treatments for severe neurodegenerative and inflammatory disorders, including Alzheimer’s and Huntington’s disease.
